Filing Flows › bioAffinity Technologies (BIAF) › Q4 2025
bioAffinity Technologies (BIAF) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 16, 2026
bioAffinity Technologies (BIAF) reported revenue of $1.6M for the fourth quarter 2025 (Q4 2025), -28% from a year earlier and +10% from the quarter before. Operating margin was -196.9%, net loss $3.1M (197.0% of revenue).
bioAffinity Technologies, Q4 2025: revenue $1.6M (-28% year over year), operating margin -196.9%, net loss $3.1M, operating cash flow −$2.6M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.6M | +10% | -28% |
| Operating profit | −$3.1M | — | — |
| Net earnings | −$3.1M | — | — |
| Operating cash flow | −$2.6M | — | — |
What changed
Revenue was $1.6M in Q4 2025, down 28% year over year and up 10% from the previous quarter. Health Care, Patient Service was the largest line at 81% of revenue.
Operating costs exceeded revenue by $3.1M, an operating margin of -196.9%. Total costs fell 8% while revenue fell 28%. The quarter ended with a net loss of $3.1M, narrower than the previous quarter's $5.1M loss.
Operating cash flow was −$2.6M. Non-cash charges added back $124K of depreciation and amortization and $66K of share-based compensation. Working capital and other items added $388K. Capital expenditures of $0K exceeded it, leaving free cash flow of −$2.6M.
Questions
What was bioAffinity Technologies' revenue in the fourth quarter 2025?
bioAffinity Technologies (BIAF) reported revenue of $1.6M for the fourth quarter 2025 (Q4 2025), -28% from a year earlier and +10% from the quarter before.
Was bioAffinity Technologies profitable in the fourth quarter 2025?
Operating loss was $3.1M (-196.9% of revenue) and net loss $3.1M.